Participated · Equity · Feb 2026

Taiv installs proprietary edge hardware in bars, restaurants, and similar venues, using computer-vision models to detect when a televised game cuts to commercial and replacing the national spot with venue-specific or paid programmatic ads in under 100 milliseconds. The system supports advanced features such as “sports-moment targeting,” allowing advertisers to trigger creative based on real-time game context and audience sentiment. The network now spans nearly 5,000 venues across North America and has maintained almost 3× year-over-year growth. Advertisers on the platform include major brands such as T-Mobile, Fox, Google, FanDuel, and Pepsi. Headcount expanded from about 30 to 85 employees over the past year, with plans to add roughly 25 more, primarily in sales and product. To date, Taiv has raised more than $30 million in capital and is valued at just under $100 million, giving the company resources to fund additional hardware and accelerate nationwide rollout.

Participated · Equity · Jun 2021

Zipline builds and operates autonomous fixed-wing drone systems to deliver packages, with a track record of medical supply deliveries in Africa and expanding consumer deliveries in the U.S. Its commercial roster includes partners such as Walmart and more than a dozen restaurant brands including Panera, Chipotle, and Wendy’s. The company operates across four continents and has completed about two million deliveries to date. Financially, Zipline closed an extended $800 million Series H earlier this year and was most recently valued at $7.6 billion. Under its new strategic partnership with Uber, Zipline will integrate with Uber Eats and begin deliveries in existing U.S. markets later this year, aiming to scale rapidly toward a target of one million daily deliveries by 2029. The deal is intended to accelerate mainstream adoption by pairing Zipline’s infrastructure and regulatory approvals in select markets with Uber’s on-demand marketplace.

Participated · Series D · Jan 2010

EyeGate Pharma develops ocular therapeutics and is advancing a pipeline using its proprietary EyeGate® II Delivery System, a non-invasive iontophoretic drug delivery platform. Its lead program, EGP-437, is a dexamethasone‑derived corticosteroid solution formulated to treat Dry Eye Syndrome (DES). The company raised an additional $5.9M as part of its Series D, bringing the Series D total to $28.5M to date. These funds will be used to continue development of EGP-437. The ALLUVION Phase III study of EGP-437 is fully enrolled and is awaiting last patient last visit, with top-line data expected by the end of Q1 2011. A prior Phase II study showed significant improvements in signs and symptoms of dry eye during and after Controlled Adverse Experiment exposure. EyeGate Pharmaceuticals is a Waltham, MA-based company developing ocular therapeutics and a proprietary non-invasive iontophoretic drug delivery system (EyeGate® II). The company is advancing EGP-437, a dexamethasone-derived corticosteroid solution, for the treatment of Dry Eye Syndrome (DES). According to EyeGate, EGP-437 significantly improved the signs and symptoms of DES in a Phase II clinical study. A pivotal study was expected to begin in the first half of 2010. EyeGate raised $22.6M in Series D financing, with $11M available immediately and $11.6M held in reserve. The new capital will support continued development of EGP-437 and the company’s pipeline using its EyeGate II delivery system.